A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth - PubMed (original) (raw)
A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth
Lee M Greenberger et al. Mol Cancer Ther. 2008 Nov.
Abstract
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that plays a critical role in angiogenesis, survival, metastasis, drug resistance, and glucose metabolism. Elevated expression of the alpha-subunit of HIF-1 (HIF-1alpha), which occurs in response to hypoxia or activation of growth factor pathways, is associated with poor prognosis in many types of cancer. Therefore, down-regulation of HIF-1alpha protein by RNA antagonists may control cancer growth. EZN-2968 is a RNA antagonist composed of third-generation oligonucleotide, locked nucleic acid, technology that specifically binds and inhibits the expression of HIF-1alpha mRNA. In vitro, in human prostate (15PC3, PC3, and DU145) and glioblastoma (U373) cells, EZN-2968 induced a potent, selective, and durable antagonism of HIF-1 mRNA and protein expression (IC(50), 1-5 nmol/L) under normoxic and hypoxic conditions associated with inhibition of tumor cell growth. Additionally, down-regulation of HIF-1alpha protein by EZN-2968 led to reduction of its transcriptional targets and of human umbilical vein endothelial cell tube formation. In vivo, administration of EZN-2968 to normal mice led to specific, dose-dependent, and highly potent down-regulation of endogenous HIF-1alpha and vascular endothelial growth factor in the liver. The effect can last for days after administration of single dose of EZN-2968 and is associated with long residence time of locked nucleic acid in certain tissues. In efficacy studies, tumor reduction was found in nude mice implanted with DU145 cells treated with EZN-2968. Ongoing phase I studies of EZN-2968 in patients with advanced malignancies will determine optimal dose and schedule for the phase II program.
Similar articles
- Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Sapra P, Kraft P, Pastorino F, Ribatti D, Dumble M, Mehlig M, Wang M, Ponzoni M, Greenberger LM, Horak ID. Sapra P, et al. Angiogenesis. 2011 Sep;14(3):245-53. doi: 10.1007/s10456-011-9209-1. Epub 2011 Mar 31. Angiogenesis. 2011. PMID: 21452059 Free PMC article. - Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma.
Borsi E, Perrone G, Terragna C, Martello M, Dico AF, Solaini G, Baracca A, Sgarbi G, Pasquinelli G, Valente S, Zamagni E, Tacchetti P, Martinelli G, Cavo M. Borsi E, et al. Oncotarget. 2014 Apr 15;5(7):1779-92. doi: 10.18632/oncotarget.1736. Oncotarget. 2014. PMID: 24732040 Free PMC article. - Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Paradziej-Łukowicz J, Skwarska A, Peszyńska-Sularz G, Brillowska-Dąbrowska A, Konopa J. Paradziej-Łukowicz J, et al. Cancer Biol Ther. 2011 Oct 1;12(7):586-97. doi: 10.4161/cbt.12.7.15980. Epub 2011 Oct 1. Cancer Biol Ther. 2011. PMID: 21775820 - Natural products as potent inhibitors of hypoxia-inducible factor-1α in cancer therapy.
Zhong JC, Li XB, Lyu WY, Ye WC, Zhang DM. Zhong JC, et al. Chin J Nat Med. 2020 Sep;18(9):696-703. doi: 10.1016/S1875-5364(20)60008-5. Chin J Nat Med. 2020. PMID: 32928513 Review. - Small molecules targeting HIF-1α pathway for cancer therapy in recent years.
Tang W, Zhao G. Tang W, et al. Bioorg Med Chem. 2020 Jan 15;28(2):115235. doi: 10.1016/j.bmc.2019.115235. Epub 2019 Nov 29. Bioorg Med Chem. 2020. PMID: 31843464 Review.
Cited by
- Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines.
Kang J, Kim E, Kim W, Seong KM, Youn H, Kim JW, Kim J, Youn B. Kang J, et al. J Biol Chem. 2013 Sep 20;288(38):27343-27357. doi: 10.1074/jbc.M113.490482. Epub 2013 Jul 31. J Biol Chem. 2013. PMID: 23902763 Free PMC article. - Regulating the Expression of HIF-1α or lncRNA: Potential Directions for Cancer Therapy.
Zhang M, Zhang Y, Ding Y, Huang J, Yao J, Xie Z, Lv Y, Zuo J. Zhang M, et al. Cells. 2022 Sep 8;11(18):2811. doi: 10.3390/cells11182811. Cells. 2022. PMID: 36139386 Free PMC article. Review. - Synthesis and evaluation of quinazolin-4-ones as hypoxia-inducible factor-1α inhibitors.
Huang W, Huang R, Attene-Ramos MS, Sakamuru S, Englund EE, Inglese J, Austin CP, Xia M. Huang W, et al. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5239-43. doi: 10.1016/j.bmcl.2011.07.043. Epub 2011 Jul 21. Bioorg Med Chem Lett. 2011. PMID: 21831635 Free PMC article. - Novel and emerging targeted-based cancer therapy agents and methods.
Hojjat-Farsangi M. Hojjat-Farsangi M. Tumour Biol. 2015 Feb;36(2):543-56. doi: 10.1007/s13277-015-3184-x. Epub 2015 Feb 9. Tumour Biol. 2015. PMID: 25663495 Review. - Hypoxia-inducible factor-1 drives divergent immunomodulatory functions in the pathogenesis of autoimmune diseases.
Islam SMT, Won J, Khan M, Mannie MD, Singh I. Islam SMT, et al. Immunology. 2021 Sep;164(1):31-42. doi: 10.1111/imm.13335. Epub 2021 Apr 27. Immunology. 2021. PMID: 33813735 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources